Aligning mRNA Progress with Regulatory Streamlining

BioPharm Peer Exchange

Drug Solutions Podcast: 

Employing novel technologies and more patient-centric approaches

Integrating Strategies for Formulation Success

Delving into Biopharmaceutical Development and Manufacturing

Drug Digest: 

 Quality Considerations in Changing Excipient Providers

Ask the Expert

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

Science laboratory test tubes , laboratory equipment | Image Credit: © BillionPhotos.com - stock.adobe.com

Recipharm, a global contract development and manufacturing organization (CDMO) headquartered in Stockholm, Sweden, announced in a press release on Sept. 16, 2024 that it was making what the company called a “significant” investment in its Oral Solid Development and Pilot Scale Centre in Zwickau, Germany (1).

Among the main objectives of the investment are three new good manufacturing practice (GMP) pilot-scale suites for blending, tableting, and hard capsule filling, which Recipharm said will complement the facility’s existing GMP pilot-scale functions for both dry and wet granulation, and related tools for material science and characterization (1).

By making these upgrades, Recipharm said it hopes to position its Zwickau location as the “ideal partner” for such things as API and excipient characterization, clinical Phases II and III supply, lifecycle management, product and process development, product optimization, scale-up and tech transfers, and small-scale batch manufacturing (1).

The September 16 announcement comes less than two weeks after Recipharm introduced a platform for quality by design (QbD) called ReciPredict, which has three key goals, according to the company: providing an API consumption reduction of between 30% and 70% during development and scale-up, reducing the time to clinical stage by up to six months, and enabling a “fully integrated” approach to QbD (2).

ReciPredict, Recipharm said, will combine expertise in data science and statistics with robust statistical and modeling tools—the advanced statistical models, leveraged therein, connecting critical process parameters with material and drug product quality attributes (2). Both ReciPredict and the investments announced for the Zwickau facility are being positioned by Recipharm as efforts to streamline the product development cycle, from initial formulation to manufacturing, and increase the efficiency and reliability with which such products are able to be delivered to the pharmaceutical industry.

"With these advancements, we can now offer late-stage product development, clinical supply, and commercial manufacturing from a single site,” Uwe Hanenberg, PhD, Recipharm head of product implementation, said in the press release. “This integration makes it more efficient and cost-effective for our customers, providing them with access to top experts, while ensuring efficiencies in material consumption, including APIs. With our investment in ReciPredict as well as the GMP pilot scale for dry granulation and now the pilot scale for dry technologies, we have the tools and equipment at hand to support our custom with a faster clinic-to-market timeline for new drugs and de-risking manufacturing, ensuring greater certainty in meeting customer needs."

As far as a timeline for these improvements, Recipharm said the new pilot-scale center for dry technologies would be GMP-ready by the first quarter of 2025 (1).

The Zwickau branch is just one of Recipharm’s 21 locations worldwide, including two in the United States, in Boxborough and Watertown, both in Massachusetts.

1. Recipharm. Recipharm’s Investment Enhances Efficiency and Speed for Customers and Patients. Press Release. Sept. 16, 2024.
2. Recipharm. Introducing ReciPredict: Revolutionizing Drug Product Development and Manufacturing. Press Release. Sept. 4, 2024.

Articles

The company said this new commitment to its facility in Germany goes hand in hand with its recently announced ReciPredict, an initiative intended to streamline the product development cycle.

Recipharm Investment Will Enhance Oral Solid Development, GMP Pilot-Scale Suites

Communication between the manufacturing plant and retail stores. | Image Credit: © Cagkan - © Cagkan - stock.adobe.com

Korro Bio, a Massachusetts-based biopharmaceutical company that develops genetic medicines based on RNA editing, announced on Sept. 16, 2024 that it is collaborating with Novo Nordisk to develop targets to treat cardiometabolic diseases, such as obesity, diabetes, and cardiovascular diseases. Novo Nordisk will use Korro’s Oligonucleotide Promoted Editing of RNA (OPERA) platform as part of the collaboration.

According to Korro, “RNA editing can specifically and efficiently modulate protein function, potentially enabling access to previously undruggable targets for cardiometabolic diseases” (1). The company’s OPERA program uses “an oligonucleotide to co-opt a natural process in the human body to make changes in mRNA [messenger RNA] encoding the protein, leaving the DNA genome unaltered, thus aiming to bring a pharmacologically titratable approach using genetic medicine” (1).

“Novo Nordisk is a global leader in the discovery, development and commercialization of therapies for cardiometabolic diseases,” said Dr. Ram Aiyar, CEO and president of Korro, in a company press release (1). “This collaboration enables us to use our proprietary technologies and capabilities in RNA editing to develop potential new treatments for people living with chronic diseases without impacting our internal pipeline focus. This partnership will expand the opportunity to potentially bring targeted RNA editing to diseases with high prevalence.”

“We are excited to partner with Korro on its differentiated RNA editing platform as we explore novel technologies to address the unmet need for people living with cardiometabolic diseases,” said Uli Stilz, head of Novo Nordisk’s Bio Innovation Hub, in the Korro press release. “Korro’s platform aims to enable a titratable, transient, and highly specific editing approach at the RNA level which has the potential to transform care. With our deep knowledge of cardiometabolic diseases and Korro’s unique approach, we have the opportunity to establish a new paradigm of treatment modalities for cardiometabolic diseases by addressing otherwise undruggable targets.”

Korro is eligible to receive up to $530 million in upfront, development, and commercial milestone payments as part of the deal. The company will also receive tiered royalties and R&D funding. Preclinical development will be handled by Korro with Novo Nordisk advancing the treatment through clinical studies.

This collaboration adds onto Novo Nordisk’s recent plans to increase treatments for these types of diseases. In June 2024, the company announced it was expanding its facility in Clayton, NC, investing $4.1 billion (approximately DKK27 billion) in a fill/finish manufacturing facility to increase its production of current and future injectable therapeutics for treating obesity and other serious chronic diseases. The investment is one of the largest the company has made and will include 1.4 million square feet of production space for aseptic manufacturing and finished production processes, doubling the combined square footage at the company’s existing facilities in North Carolina. The new facility is expected to be completed in 2029 (2).

“It took us a century to reach 40 million patients, but through this expansion and continued investment in our global production, we’re building Novo Nordisk’s ability to serve millions more people living with serious chronic diseases in the future,” said Lars Fruergaard Jørgensen, president and CEO of Novo Nordisk, in the press release (2). “This is yet another real signal of our efforts to scale up our production to meet the growing global need for our life-changing medicines and the patients of tomorrow.”

Korro Bio. Korro Bio Announces Collaboration with Novo Nordisk to Develop Two Therapeutic Candidates. Press Release. Sept. 16, 2024.

Novo Nordisk. Novo Nordisk Announces 4.1 Billion USD Investment to Expand US Manufacturing Capacity. Press Release. June 24, 2024.

Novo Nordisk will use Korro Bio’s OPERA platform to develop RNA editing candidates for two targets to treat cardiometabolic diseases.

Korro Bio and Novo Nordisk Collaborate on Cardiometabolic Treatments

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - stock.adobe.com

The API Innovation Center, a St. Louis-based nonprofit with a mission to enable delivery of a market-competitive commercial supply of United States-made APIs, announced in a press release on Sept. 12, 2024 that it has received $14 million from the Administration for Strategic Preparedness and Response’s (ASPR) Center for Industrial Base Management and Supply Chain (IBMSC) to lead development and US production of three critical APIs (1–2).

ASPR, which is under the US Department of Health and Human Services (HHS), also announced the agreement on Sept. 12, saying it is part of an effort first previewed in November 2023 to make more essential medicines in the US, hoping to mitigate drug shortages in the interest of national defense (3).

"This funding represents both a financial commitment and a significant step towards securing America’s pharmaceutical resiliency and patient access to critical medicines,” Tony Sardella, chair and founder of APIIC, said in the APIIC press release. “By focusing on developing these high-impact molecules, we are creating a private-public blueprint for driving self-reliance that is essential for national health security and can be replicated across the country.”

The APIs, chosen in part for their role in US healthcare as well as their shortage history, are albuterol, which is used to treat asthma and other respiratory conditions; desmopressin acetate, which treats diabetes and blood coagulation issues; and lorazepam, which is used to treat anxiety (1). Partners with APIIC in this endeavor include Mallinckrodt Specialty Generics, Apertus Pharmaceuticals, MilliporeSigma, and the University of Missouri–St. Louis (UMSL).

“Partnering with the API Innovation Center on this important initiative allows us to leverage our strengths in research, workforce development, and community engagement to support a more secure and self-reliant pharmaceutical supply chain,” Chris Spilling, PhD, UMSL vice chancellor for research and economic and community development, said in the APIIC press release. “UMSL is proud to play a key role in advancing these critical efforts, which will have lasting impacts on both our region’s economy and the nation’s health security.”

According to APIIC, at least 83% of the top 100 generic medicines in the US have no domestic-based source for the small-molecule APIs common in current medications (1). Domestic facilities are operating below capacity, leaving the country at the whims of foreign manufacturers, their shortages, and geopolitical conflicts.

“The award we are announcing today enables a domestic supply chain that provides on-demand manufacturing for essential medicines,” said ASPR Assistant Secretary for Preparedness and Response Dawn O’Connell, in the HHS press release. “We are committed to using innovative and flexible domestic manufacturing to increase capacity and reduce reliance on foreign sources.”

1. APIIC. The API Innovation Center Receives $14 Million in Strategic Funding to Bolster US Pharmaceutical Independence. Press Release. Sept. 12, 2024.
2. APIIC. About—API Innovation Center. 

 (accessed Sept. 13, 2024).
2. ASPR. Biden-Harris Administration Funds First Defense Production Act Title III Award to Onshore Manufacturing of Ingredients for Essential Medicines. Press Release. Sept. 12, 2024.

The critical APIs that this funding will contribute to are used in the treatment of asthma, diabetes, and anxiety disorders.

APIIC Receives $14M Award for Development, Production of Three APIs

Brewerton, NY-based Pacteon Group announced in a press release on Sept. 9, 2024 that in advance of Pack Expo 2024, a trade show focusing on the packaging and processing industry that will take place from Nov. 3–6, 2024 in Chicago, the company had added Descon Conveyor Systems to its portfolio and would be displaying a Descon product at one of its Pack Expo booths (1–2).

Called the Single-Lane Empty Can Vacuum Transfer with Laser Coding and Code Inspection, this solution is designed to deliver reliable and high-quality laser coding of empty cans prior to rinsing in a dry location of the production facility (1). The empty cans are held by their tops, allowing access to the laser coding components on the bottom, and by traveling in one lane, offering customers an opportunity for empty can quality inspection immediately following vacuum transfer.

“The solution offers superior quality assurance and prevents line stoppages by automatically removing defective empty cans with improper date code, dented or damaged flanges from the line prior to filling,” Jeff Philpott, Descon VP of operations, said in the Pacteon press release.

Booth S-3300, where Pacteon will be exhibiting the new Descon product, is located in the “Inventor’s Corner” at Pack Expo, and Descon software will also be shown in action there to give attendees a sense of Pacteon’s capability to enhance packaging technology and operations (1). Additionally on display at this booth will be the Collaborative Case Erector-Palletizer from Schneider Packaging Equipment, another entity in Pacteon’s portfolio. The 3D-printed, lightweight, end-of-arm tool used in this solution allows for fast and tool-less changeover—one operator in under five minutes—with the end results of more productive labor tasks and reduction of repetitive motion injuries, according to the press release (1).

“Our adaptable new system consolidates case erecting, taping, and palletizing for a broad range of case sizes and weights,” Jamie Barber, director of R&D for Schneider Packaging, said in the press release. “Zero-programming setup is quick and easy by just entering the case sizes.”

The booth in the Inventor’s Corner will also display Schneider’s fully automated Robotic Case Packer and High Speed Palletizing Tool. Phoenix Stretch Wrappers, yet another of Pacteon’s partners, will have a variety of stretch wrapping options on display, including high-speed and semi-automatic models (1).

At another booth, W-16041 in the Healthcare Packaging Pavilion, Pacteon plans to showcase ESS Technologies’ Model V30 Robotic Case Packer, intended to accommodate serialization track-and-trace systems (1). Another Phoenix model stretch wrapper will also be displayed at this booth.

Pacteon said that, at both of these booths for the duration of their exhibits, company engineers would be on hand to answer questions about integration for new and existing packaging lines, sharing their expertise on precision collating and packing across pharmaceutical as well as other sectors.

1. Pacteon Group. Pacteon Exhibits New Packaging Automation Solutions at Pack Expo International 2024. Press Release. Sept. 9, 2024.
2. PMMI, The Association for Packaging and Processing Technologies. Pack Expo 2024—Packaging Trade Show in Chicago, IL. 

Descon Conveyor Systems is joining Pacteon’s portfolio, and its product will be shown alongside those from Schneider Packaging Equipment and Phoenix Stretch Wrappers.

Pacteon Adds to Automation Solution Exhibit for Pack Expo 2024

In advance of CPHI Milan, which will take place Oct. 8–10, 2024, new data gleaned from the CPHI Annual Industry Survey indicates that for the first time, within the next three years, approvals for complex molecules will outpace those of small molecules, as detailed in a press release from CPHI on Sept. 12, 2024 (1).

This information is built on trends observed in 2023, when CPHI said 17 biologics and nine tides (five peptides and four oligonucleotides) jointly accounted for nearly half of 55 new drug approvals (1).

Additionally, the press release said, contract development and manufacturing organizations (CDMOs) focused on biologics and tides are projected to be the fastest-growing sector in the pharmaceutical industry in the next five years (1). Biologics (53%) and tides (43%) were surveyed to be the best choices for CDMO investment, ahead of small molecules (35%) and antibody-drug conjugates, which CPHI said finished a surprising last of the choices in this category, polling at just 15%.

“We are observing this trend firsthand at CPHI Milan, both in terms of exhibitor evolution and in the demand for increased biological and complex therapy focused content,” Tara Dougal, CPHI Milan brand and content director, said in the press release. “Notably, there has been no contraction in the small-molecule CDMO space. Instead, we've seen a steady influx of new CDMOs at CPHI, with many mid- and large-sized CROs [contract research organizations] and CDMOs also investing in capacity for both tides and mAbs [monoclonal antibodies].”

In the survey, 62% of industry experts said they felt that continuous bioprocessing was the technology that would most help to lower mAb production costs between now and the end of the decade, leapfrogging previously prevalent methods like new cell lines (27%) and perfusion (7%) (1).

“CPHI Milan is now an integral component of the industry’s development pathway, and we are consistently looking at new ways for both our attendees and exhibitors to meet more potential partners,” Dougal said.

CPHI Milan marks its 35th anniversary in 2024 and is expected to draw 62,000 attendees and 600 CDMOs from 170 countries, with more than 150 speakers, 2500 exhibitors, and 100 content sessions—billing itself as the largest annual gathering for the contract services market (1–2). Organizers have pointed to the Next-Gen Bio Theatre as a highlight of the upcoming event, where sessions will be hosted on topics such as messenger RNA vaccines for advancing immunity and global trends in biomanufacturing.

“We’re seeing that alongside changes in the drug discovery pipeline, our bio exhibitor base at CPHI Milan is growing,” Dougal said in the release. “With newer modalities requiring sophisticated manufacturing approaches and a high level of technical expertise, choosing the right outsourcing partner is extremely important for the road to commercialization. It’s why we have seen many new audiences at the event as these drugs are often developed by biotechs and/or in smaller collaborations that need wider contract services networks to advance.”

1. CPHI. CPHI Annual Report 2024: CPHI Milan Report Predicts BLA and Tides Approvals Will Surpass Small Molecules Within the Next Three Years. Press Release. Sept. 12, 2024.
2. CPHI Milan. At the Heart of Pharma–CPHI Milan. 

Seventeen biologics and nine tides—five peptides and four oligonucleotides—were approved in 2023 alone, with further growth predicted.

CPHI Report: Biologics, Tides Approvals Will Surpass Small Molecules by 2027

Feliza Mirasol is the science editor for 

On Sept. 9, 2024, Sartorius announced the launch of its Vivaflow SU tangential flow filtration (TFF) cassette. The Vivaflow SU is designed to be more user-friendly and to allow for more flexibility in laboratory workflows. The new cassette offers more efficient and sustainable ultrafiltration and diafiltration processes for feed volumes in the range of 100 mL–1000 mL.

According to a company press release, the new all-in-one cassette reduces cost and complexity and streamlines workflows for molecule isolation in a sustainable manner. Each cassette is ready to use and has a standard laboratory pump, which enables simple set-up. The simplified set-up avoids the need for expensive systems and expensive process optimization and allows for faster and more reliable concentration and rebuffering of any molecule. The cassette also eliminates the need for cleaning and reduces contamination risk while minimizing waste, according to the press release.

“Vivaflow SU is a testament to our promise to always simplify progress,” said John Cashman, product manager for Lab Ultrafiltration at Sartorius, in the press release. “It takes the ease-of-use that our customers already value about TFF with Vivaflow and elevates the experience with improved handling and performance, while reducing waste. Our next-generation cassette eliminates the need for feed flow rate, TMP [transmembrane pressure], and permeate flux calculations, while also offering sustainability improvements that are truly impressive for a single-use consumable.”

Sustainability features of the new cassette include a new housing that uses 30.5% less plastic. It also incorporates several eco-friendly design improvements, such as locally sourced raw materials, customized tubing kits for each cassette configuration, a digital user manual, and reduced non-recyclable packaging; all these design elements contribute to a lower research footprint, the company stated in the press release.

Vivaflow SU is the-next-generation TFF cassette that replaces the previous Vivaflow 50. It is meant for research scientists who require a fast and reliable means for concentrating and rebuffering large feed volumes in molecule isolation workflows.

The launch of Vivaflow SU follows on the heels of Sartorius’ earlier launch of the Arium Mini Extend water purification system for laboratories in June 2024 (1). The Arium Mini Extend is the newest member of the Arium Mini product line. The new purification system is designed to meet the Type 1 water demands of laboratories for general, life-science, and analytical applications, according to the company in a press release. The new system is compact and offers ultrapure water purification with flexibility and convenience.

The new system comprises a flexible, ergonomic handheld dispenser, a user-friendly digital display, and the Arium Bagtank technology to significantly optimize laboratory workflows. The dispensing unit is equipped with an independent volume control function and expands the access area for ultrapure water. The new system streamlines water purification processes, especially those processes that require repeated dispensing. Meanwhile, operation and maintenance have been made simpler with intuitive menus and a 5-L Bagtank for storage of purified water. These features facilitate cleaning procedures and ensure uninterrupted laboratory workflows, the company stated in its press release.

1. Sartorius. Sartorius Launches New Arium Mini Extend with Flexible Arm for Versatile Type 1 Water Dispensing. Press Release. June 17, 2024.

Sartorius' new Vivaflow SU tangential flow filtration cassette offers better flexibility in lab workflows and is designed to be more user-friendly. 

Sartorius Introduces New TFF Cassette that Offers Streamlined Workflow in the Lab

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

On Tuesday, Sept. 10, 2024, Nicholas Violand, director of Enterprise Regulatory Compliance at Johnson & Johnson, and Paul Palmer, managing director and pharmaceutical consultant at Paul R. Palmer Limited, gave presentations on challenges that may arise with aging pharmaceutical manufacturing facilities at the PDA/FDA Joint Regulatory Conference in Washington, DC.

Violand’s presentation focused on industry challenges for aging facilities, equipment risks, identifying such risks, and improving controls (1). He pointed out that drug shortages caused by outdated equipment and facilities are still a relevant problem, according to FDA, and that facility inspection issues are a “fast growing factor” in complete response letters for biologics license applications. Higher operating costs, risk of product rejections, and recalls for non-compliance may be associated with large, outdated facilities, according to Violand.

Some key risks involved in aging facilities that Violand pointed to are conditions such as temperature, mold, damage, and a lack of cleaning and maintenance. Damaged or deteriorating equipment may lead to quality defects, visibly unclean equipment can be difficult to validate, and poor facility design may lead to contamination, he said.

To mitigate some of these issues, Violand recommended business partnering and open lines of communication and oversight as crucial elements. He pointed to strategic planning to ensure baseline resource allocation. He also suggested internal and external site monitoring programs to identify risks involved in an aging facility.

Palmer’s presentation included two case studies involving aseptic facilities (2). He detailed environmental monitoring failures found at one of the facilities, which had recently experienced a change of ownership, that included squishy floors, mold, broken seals in windows, and a variety of other problems, including cheap fixes, during a consultation audit of the facility.

After their presentations, Violand and Palmer were joined by Sandra Boyd, drug national expert, OMPTO, ORA, FDA, for a Q&A session. The topic of limited capital was raised and what best practices can be used. Boyd said quality culture is “huge,” and it permeates throughout a company. If quality culture is good, then quality is a priority.

Violand said one should identify the problem and the risk associated with it. Most facility- and equipment-related action plans are not immediate, and one should contain the problem and then earmark it for the future to identify what can be done to fix it in the future, using metrics, etc., he said. Looking at the consequences can help decide to make an investment.

The question of FDA expectations for contract manufacturing organizations to transition to newer aseptic technologies in the future arose. Boyd commented that FDA inspectors will focus on old technologies, such as open restricted access barrier systems, instead of newer technology like isolators, which are difficult to maintain. Companies should not wait for FDA inspectors to come in and point out old technology, suggested Boyd, and she also said it’s a good idea to get an outside perspective on processes to see where things may be not ideal.

Violand cautioned that when FDA sees an open process, the inspector will spend time watching that process and will see things are outdated that may have gaps and, therefore, risk.

Violand, N. Risk Communication: Addressing Aging Facility Concerns to Ensure Sustainable Product Quality. Presentation at the PDA/FDA Joint Regulatory Conference 2024. Sept. 10, 2024.

Palmer, P. Aseptic Facility Communication and Assessment. Presentation at the PDA/FDA Joint Regulatory Conference 2024. Sept. 10, 2024.

During a presentation at the PDA/FDA Joint Regulatory Conference, Nicholas Violand of Johnson & Johnson and Paul Palmer of Paul R. Palmer Limited discussed how aging facilities can impact the quality of pharmaceutical products.

PDA/FDA Joint Regulatory Conference: Product Quality Risk in Aging Facilities

Grace as a CDMO

Bob Hughes and Brian Graves sat down with 

to highlight key elements of working alongside Grace. Learn more about:

How with 40 years of experience in the CDMO space, Grace is a collaborative partner with their customers throughout the entire project, from the lab to commercial-scale production

Grace's well-established, systematic processes for executing your next small molecule API project

Grace’s Fine Chemical Manufacturing Services (FCMS) and the technical expertise & operational capabilities to support your next project

Videos

Bob Hughes (Research Fellow, Grace) and Brian Graves (Global Business Manager, Fine Chemicals, Grace) explain how Grace's experience as a CDMO can help customers from the lab to full-scale production. 

Grace: Your API CDMO Partner of Choice

Editorial Advisory Board Spotlight: Susan J. Schniepp

The PharmTech Group’s Editorial Advisory Boards (EABs) provide our editors with expert insights into the development, manufacturing, and quality issues impacting the bio/pharmaceutical industry. EAB members offer valuable input to our editors by reviewing editorial submissions and advising on relevant topics for the magazines and our websites.

This Editorial Advisory Board Spotlight features Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, a Nelson Labs company. Susan has been a member of the EAB for several years and a regular contributor to our Ask the Expert print and video series. Susan has offered thought leadership and expert insight into quality and regulatory concerns for our publications. She has also served as the past-chair of the Parenteral Drug Association and was previously a chair with the US Pharmacopeia.

Click the video above to learn more about Susan and her views on the industry.

Click here to access the Ask the Expert series.

Susan J. Schniepp, member of the editorial advisory boards for Pharmaceutical Technology, Pharmaceutical Technology EuropeT, and BioPharm International, provides an update on her experience working in the pharmaceutical industry and what she sees for the industry’s future. 

On Sept. 6, 2024, CPHI Milan announced the finalists for the 2024 CPHI Pharma Awards. The ceremony will be held on the event’s opening evening at the CPHI Celebration. CPHI Milan will run October 8–10, 2024.

A key feature of the CPHI Celebration, the awards ceremony spans 14 categories and celebrates excellence and innovation in the pharmaceutical industry. The 2024 awards highlight two new categories: a new "Woman of the Year" award and a new "Future Leader" award.

The Woman of the Year award honors women leaders who inspire colleagues, champion diversity and inclusion, and advocate for industry progression. Nominees are evaluated based on leadership ability, collaboration skills, and ability to create opportunities for women while challenging the status quo. The Future Leader award recognizes rising stars who are under 35 years of age and who have at least five years of experience in pharma, biopharma, or academic institutions. The award commends those who bring fresh perspectives to the table, manage teams effectively, and introduce innovative ideas. The winners of this award are marked as the future leaders who are anticipated to shape the pharmaceutical industry with dedication and vision.

The shortlist for this year’s awards includes the following:

ProPharma Group/PBL for the Cell Factory Box (CF Box)

Haemopharm Healthcare s.r.l for RIGENERA, an innovative tissue regenerating technology

Akums Drugs and Pharmaceuticals for hydroxyurea oral suspension, the first room temperature-stable drug, according to CPHI’s press release

Merck/Millipore Sigma for the Benzonase Salt Tolerant endonuclease and Emprove Expert raw and starting materials chemical portfolio

AustinPx for its KinetiSol Technology, used for improving bioavailability of poorly soluble drugs

Thermo Fisher Scientific for the RoSS.FILL CGT, a fully automated filling and filtration system that enables automated aliquoting of small volumes at highest accuracy with single-use support

Blynksolve for the Blynksolve Digital Knowledge Twin, which leverages artificial intelligence (AI) to accelerate clinical trials for large pharma

Ministry of Industry and Mineral Resources, Kingdom of Saudi Arabia for its Pharmaceutical Industrial Strategy Acceleration Process.

Dr. Reddy’s Laboratories for its development of a drug substance process using flow chemistry and design of a continuous manufacturing plant

Teva api for the Ozonolysis in Flow, a green and safe alternative to heavy metal-catalyzed cleavage of the carbon–carbon double bond on an industrial scale

LEON and Team Consulting for the NANOme Benchtop system, used for personalized therapies

Enzymaster for (S)-4-phenyl-oxazolidinone

Lonza for the Lonza AI-Enabled Route Scouting Service.

Thermo Fisher Scientific for its efforts in revolutionizing vaccine logistics, shelf-life, and wastage with fridge-free innovation

Unistraw Corp. for the UniLayer Straw Delivery System

Lonza for Capsugel Enprotect Size 9 capsule for pre-clinical studies

Lubrizol Life Science Health (LLS Health) for Apinovex Polymers, used for enhancing oral solubility.

Axom Solution SA for its Automated Visual Inspection Station

FABRX for its Revolutionising Care for Children: Personalized 3D Printed Medicines

Teva api for its Advanced AI Optimization for API Production

RheaVita for the RheaLyo GMP-Flex continuous freeze-dryer

Catalent Cell & Gene Therapy for the UpTempo CAR-T Cell Therapy Platform Process.

Azelis Group NV, for its novel bioadhesive oral fluid gel spray

Adare Pharma Solutions for its sprinkle formulation of a drug capsule used for treating tremors and other uncontrolled body movements

Aptar Pharma and Haleon for Otrivin Nasal Mist, a first next-generation nasal congestion device transforming experience, adherence, and effectiveness

ApiJect Syestems for its Prefilled ApiJect Injector

CurTec International for CurTec Fold Pack Pails

Colorcon for EQIUS Equilibrium RH Stabilizers

WestRock for the Cere Screen Digital Display Label

Esmark Finch for the Digital Carton Workflow for pharmaceutical cartons.

TraceLink for its Multienterprise Information Network Tower(MINT)

QYOBO GmbH for a new age of supply chain visibility and resilience

HCLTech for the HCLTech Smart Material Tracking Solution

I.E. Medica Inc. for E-Z Philippine Importation.

Nordic Bioproducts Group Ltd for Pioneering Sustainable Microcrystalline Cellulose (MCC) Production, a first-of-its-kind production facility powered by patented AaltoCell technology in Lappeenranta, Finland

Rotor Print for From Rigid Packaging to Flexible Packaging

Berry Global for its Clarified PP VMS kit

PharmaBlock Sciences for Innovation for Sustainability: Pioneering Low-carbon Manufacturing with Continuous Flow Chemistry Technology

Evonik Industries AG for its PhytoSquene plant-based squalene for parenteral applications.

RTIXIO LIFESCIENCES PVT LTD for Dvarka, a regulatory driven, AI, and automation-assisted platform for emerging market access and compliance

Eidolon Learning Pvt Ltd for SEEK, an AI-driven tool for reducing human error

ProPharma Group for Prodigy, an end-to-end technology-enabled consulting platform

ASPHALION, S.L. for its Regulatory, Scientific & Safety Consulting in Life Sciences service

Esteve Quimica for the Volta Project: who said impossible?

Vijay Ambati, Founder and CEO, Clearsynth

Nebu-Flow Nebuliser Platform by Acu-Flow Limited (t/a Nebu-Flow)

Galvita TIP, a new standard of oral drug delivery by Galvita AG.

Cipla Limited for Drone Powered Delivery for Critical Patient Care

Honey Farm, ICAS Employee Support; Deniz Kayadalen Brand Ambassador, Woodland Trust, Adalvo

Fox Chase Cancer Center and West Pharmaceutical Services, West Pharmaceutical Services.

Sigma Mostafa, PhD, Chief Scientific Officer, KBI Biopharma

Almuth Steinkühler, PhD, Chief Financial Officer, SCHOTT Pharma AG & Co. KGaA

Julia Tsetis, President and CEO, OFET group of pharmaceutical companies

Audrey Butler, Vice President, Global Operational Excellence, Adare Pharma Solutions

Neeti Pant, Managing Director & Co-Founder, DDReg Pharma Pvt Ltd

Joyce Fitzharris, Head of Small Molecule, Europe, SK pharmteco.

The 2024 CPHI Pharma Awards comprise finalists spanning 14 categories and includes awards for future leaders, women of the year, and an “at the heart of pharma” category.

Featured Content

Drug Solutions Podcast:

Integrating Strategies for Formulation Success

Drug Digest:

Ask the Expert